Literature DB >> 24493529

Response.

Sif Hansdottir, Brian K Gehlbach.   

Abstract

Mesh：

Year:  2014        PMID： 24493529      PMCID： PMC3921095          DOI： 10.1378/chest.13-2519

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

2.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

3.  Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Authors:  Diana Bonderman; Stefano Ghio; Stephan B Felix; Hossein-Ardeschir Ghofrani; Evangelos Michelakis; Veselin Mitrovic; Ronald J Oudiz; Francis Boateng; Andrea-Viviana Scalise; Lothar Roessig; Marc J Semigran
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

Review 4.  WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.

Authors:  Sif Hansdottir; Dayna J Groskreutz; Brian K Gehlbach
Journal:  Chest       Date:  2013-08       Impact factor: 9.410
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.